CUE
Cue Biopharma Inc

1,385
Mkt Cap
$45.68M
Volume
271,976.00
52W High
$1.75
52W Low
$0.5406
PE Ratio
-1.27
CUE Fundamentals
Price
$0.5408
Prev Close
$0.5802
Open
$0.59
50D MA
$0.7307
Beta
1.34
Avg. Volume
270,786.52
EPS (Annual)
-$0.7221
P/B
3.41
Rev/Employee
$226,512.20
Loading...
Loading...
News
all
press releases
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
More News
News Placeholder
CervoMed Inc. (CRVO) Reports Q3 Loss, Misses Revenue Estimates
CERVOMED INC (CRVO) delivered earnings and revenue surprises of -23.53% and -69.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·13d ago
News Placeholder
Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +133.33% and +12.67%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·14d ago
News Placeholder
Adaptive Biotechnologies (ADPT) Reports Q3 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +6.25% and +38.15%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -32.58% and +24.16%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·21d ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q2 Loss, Tops Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.77% and +47.70%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates
YmAbs Therapeutics (YMAB) delivered earnings and revenue surprises of +74.07% and +5.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
scPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Lags Revenue Estimates
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of -13.33% and -2.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates
Zacks·6mo ago
News Placeholder
Forecasting The Future: 4 Analyst Projections For Cue Biopharma
Latest Ratings for CUE DateFirmActionFromTo Nov 2020BerenbergInitiates Coverage OnBuy May 2020StifelMaintainsBuy May 2020OppenheimerMaintainsOutperform View More Analyst Ratings for CUE...
Benzinga·2y ago

Latest CUE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.